Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited)

v3.21.2
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)
$ in Thousands
Total
Cumulative Effect, Period of Adoption, Adjustment [Member]
Common Stock [Member]
Additional Paid-In Capital [Member]
Accumulated Other Comprehensive Income (Loss) [Member]
Accumulated Deficit [Member]
Accumulated Deficit [Member]
Cumulative Effect, Period of Adoption, Adjustment [Member]
Balance, beginning at Dec. 31, 2018 $ (21,708)   $ 37 $ 149,682 $ (69) $ (171,358)  
Balance, beginning (ASU 2016-02 [Member]) at Dec. 31, 2018   $ (29)         $ (29)
Balance, beginning (in shares) at Dec. 31, 2018     37,341,393        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Beneficial conversion feature relating to convertible notes 3,374     3,374      
Exercise of warrants 5     5      
Exercise of warrants (in shares)     525        
Common stock issued for cash (net of issuance cost) 2,530   $ 1 2,529      
Common stock issued for cash (net of issuance cost) (in shares)     322,920        
Conversion of notes payable to common stock 329     329      
Conversion of notes payable to common stock (in shares)     85,411        
Share-based compensation 588     588      
Exercise of stock options 1     1      
Exercise of stock options (in shares)     175        
Foreign currency translation effect 7       7    
Net income (loss) (17,408)         (17,408)  
Balance, ending at Mar. 31, 2019 (32,311)   $ 38 156,508 (62) (188,795)  
Balance, ending (in shares) at Mar. 31, 2019     37,750,424        
Balance, beginning at Dec. 31, 2018 (21,708)   $ 37 149,682 (69) (171,358)  
Balance, beginning (ASU 2016-02 [Member]) at Dec. 31, 2018   $ (29)         $ (29)
Balance, beginning (in shares) at Dec. 31, 2018     37,341,393        
Balance, ending at Dec. 31, 2019 (11,053)   $ 48 215,207 (79) (226,229)  
Balance, ending (in shares) at Dec. 31, 2019     48,471,446        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Common stock issued for cash (net of issuance cost) 142   $ 1 141      
Common stock issued for cash (net of issuance cost) (in shares)     515,743        
Fair value of warrants including down-round protection adjustments 400     600   (200)  
Share-based compensation 209     209      
Foreign currency translation effect 61       61    
Net income (loss) 5,509         5,509  
Balance, ending at Mar. 31, 2020 $ (4,732)   $ 49 $ 216,157 $ (18) $ (220,920)  
Balance, ending (in shares) at Mar. 31, 2020     48,987,189